Lutetium Lu 177 Tezuvotide Tetraxetan

**Semantic type:** Pharmacologic Substance

**Definition:** A radioconjugate composed of PSMA-10.1, a prostate-specific membrane antigen (PSMA)-targeting ligand and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration, lutetium Lu 177 tezuvotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.

**Synonyms:** - (177Lu) rhPSMA-10.1 - 177Lu Radiohybrid PSMA-10.1 - 177Lu rhPSMA-10.1 - 177Lu-rhPSMA-10.1 - LUTETIUM (177LU) TEZUVOTIDE TETRAXETAN - Lutetium (177Lu) Tezuvotide Tetraxetan - Lutetium Lu 177 PSMA-10.1